ZVRA (zevra.com) יחס שווי שוק לשווי בספרים

Zevra Therapeutics (ZVRA) generates revenue from the sale of patented treatments for sleep disorders and Niemann-Pick disease, a trend captured by the price action on the GURU.Markets chart at 2.78. The company develops therapies for rare genetic pathologies, ensuring stable sales. Its monopoly status in narrow niches transforms approved products into a consistent cash cow with no signs of decline.

This indicator allows investors to compare the market value of Zevra Therapeutics (ZVRA) with its actual equity capital, determining the extent of the premium paid for net assets. Since success in neurological pharmaceuticals depends on patents rather than general economics, the history of the company's valuation via the P/B ratio helps identify a fundamental imbalance between market expectations and the actual value of the business.